{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:28:52Z","timestamp":1793906932863,"version":"4.8.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-21934-2","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:26:24Z","timestamp":1761830784000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world survival and prognostic factors in WHO 2021 classified gliomas treated with chemo-radiotherapy"],"prefix":"10.1038","volume":"15","author":[{"given":"Mateusz","family":"Bilski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"No\u00ebl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Sm\u00f3\u0142ka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Kuncewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Ku\u017anicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loic","family":"Feuvret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Korab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Peszy\u0144ska-Piorun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Korona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izabela","family":"Baranowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Suleja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Le Fevre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Schott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Somme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma","family":"Chabli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Mesny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Mastroleo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupesh","family":"Kotecha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Jurkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Fijuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara Alicja","family":"Jereczek-Fossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamil","family":"Krystkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Harat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0141ukasz","family":"Kuncman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"issue":"8","key":"21934_CR1","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106.PMID:34185076;PMCID:PMC8328013","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis, D. N. et al. The 2021 WHO classification of tumors of the central nervous system: A summary. Neuro Oncol. 23(8), 1231\u20131251. https:\/\/doi.org\/10.1093\/neuonc\/noab106.PMID:34185076;PMCID:PMC8328013 (2021).","journal-title":"Neuro Oncol."},{"issue":"1","key":"21934_CR2","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/neuonc\/noae164","volume":"27","author":"HS Ghosh","year":"2025","unstructured":"Ghosh, H. S. et al. Contemporary prognostic signatures and refined risk stratification of gliomas: An analysis of 4400 tumors. Neuro-Oncology 27(1), 195\u2013208. https:\/\/doi.org\/10.1093\/neuonc\/noae164 (2025).","journal-title":"Neuro-Oncology"},{"issue":"2","key":"21934_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.14791\/btrt.2022.0001.PMID:35545827;PMCID:PMC9098981","volume":"10","author":"YZ Kim","year":"2022","unstructured":"Kim, Y. Z., Kim, C. Y. & Lim, D. H. The overview of practical guidelines for gliomas by KSNO, NCCN, and EANO. Brain Tumor Res. Treat. 10(2), 83\u201393. https:\/\/doi.org\/10.14791\/btrt.2022.0001.PMID:35545827;PMCID:PMC9098981 (2022).","journal-title":"Brain Tumor Res. Treat."},{"key":"21934_CR4","unstructured":"https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cns.pdf"},{"issue":"13","key":"21934_CR5","doi-asserted-by":"publisher","first-page":"1274587","DOI":"10.3389\/fonc.2023.1274587.PMID:37916157;PMCID:PMC10616854","volume":"17","author":"K Szklener","year":"2023","unstructured":"Szklener, K., Bilski, M., Nieoczym, K., Ma\u0144dziuk, D. & Ma\u0144dziuk, S. Enhancing glioblastoma treatment through the integration of tumor-treating fields. Front. Oncol. 17(13), 1274587. https:\/\/doi.org\/10.3389\/fonc.2023.1274587.PMID:37916157;PMCID:PMC10616854 (2023).","journal-title":"Front. Oncol."},{"key":"21934_CR6","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae213","author":"MJ van den Bent","year":"2024","unstructured":"van den Bent, M. J. et al. Updated EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection\u2014Update 1. Neuro-Oncology https:\/\/doi.org\/10.1093\/neuonc\/noae213 (2024).","journal-title":"Neuro-Oncology"},{"issue":"21","key":"21934_CR7","doi-asserted-by":"publisher","first-page":"5377","DOI":"10.3390\/cancers14215377","volume":"14","author":"K Szklener","year":"2022","unstructured":"Szklener, K. et al. New directions in the therapy of glioblastoma. Cancers (Basel). 14(21), 5377. https:\/\/doi.org\/10.3390\/cancers14215377 (2022).","journal-title":"Cancers (Basel)."},{"issue":"4","key":"21934_CR8","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.ijrobp.2021.07.1695","volume":"111","author":"PJJ Damen","year":"2021","unstructured":"Damen, P. J. J. et al. The influence of severe radiation-induced lymphopenia on overall survival in solid tumors: A systematic review and meta-analysis. Int. J. Radiat. Oncol. Biol. Phys. 111(4), 936\u2013948. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.07.1695 (2021).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"21934_CR9","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13014-023-02393-3","volume":"19","author":"AM Saeed","year":"2024","unstructured":"Saeed, A. M. et al. Systematic review and pooled analysis of the impact of treatment-induced lymphopenia on survival of glioblastoma patients. Radiat. Oncol. 19(1), 36. https:\/\/doi.org\/10.1186\/s13014-023-02393-3 (2024).","journal-title":"Radiat. Oncol."},{"key":"21934_CR10","doi-asserted-by":"publisher","first-page":"29345","DOI":"10.1038\/s41598-024-80656-z","volume":"14","author":"M Bilski","year":"2024","unstructured":"Bilski, M. et al. miR-200 family as new potential prognostic factor of overall survival of patients with WHO G2 and WHO G3 brain gliomas. Sci. Rep. 14, 29345. https:\/\/doi.org\/10.1038\/s41598-024-80656-z (2024).","journal-title":"Sci. Rep."},{"key":"21934_CR11","first-page":"2825","volume":"12","author":"F Pedregosa","year":"2011","unstructured":"Pedregosa, F. et al. Scikit-learn: Machine learning in Python. J. Mach. Learn. Res. 12, 2825\u20132830 (2011).","journal-title":"J. Mach. Learn. Res."},{"key":"21934_CR12","doi-asserted-by":"crossref","unstructured":"Seabold S, Perktold J (2010) Statsmodels: econometric and statistical modeling with Python. In: Proceedings of the 9th Python in Science Conference 57\u201361. Available from: https:\/\/conference.scipy.org\/proceedings\/scipy2010\/seabold.html","DOI":"10.25080\/Majora-92bf1922-011"},{"issue":"40","key":"21934_CR13","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.21105\/joss.01317","volume":"4","author":"C Davidson-Pilon","year":"2019","unstructured":"Davidson-Pilon, C. Lifelines: Survival analysis in Python. J. Open Source Softw. 4(40), 1317. https:\/\/doi.org\/10.21105\/joss.01317 (2019).","journal-title":"J. Open Source Softw."},{"issue":"3","key":"21934_CR14","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1213\/ANE.0000000000003653","volume":"127","author":"P Schober","year":"2018","unstructured":"Schober, P. & Vetter, T. R. Survival analysis and interpretation of time-to-event data: The tortoise and the hare. Anesth. Analg. 127(3), 792\u2013798. https:\/\/doi.org\/10.1213\/ANE.0000000000003653 (2018).","journal-title":"Anesth. Analg."},{"issue":"3","key":"21934_CR15","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0167-9473(98)00092-2","volume":"30","author":"C Contal","year":"1999","unstructured":"Contal, C. & O\u2019Quigley, J. An application of changepoint methods in studying the effect of age on survival in breast cancer. Comput. Stat. Data Anal. 30(3), 253\u2013270. https:\/\/doi.org\/10.1016\/S0167-9473(98)00092-2 (1999).","journal-title":"Comput. Stat. Data Anal."},{"issue":"12","key":"21934_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0051862","volume":"7","author":"J Budczies","year":"2012","unstructured":"Budczies, J. et al. Cutoff Finder: A comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS ONE 7(12), e51862. https:\/\/doi.org\/10.1371\/journal.pone.0051862 (2012).","journal-title":"PLoS ONE"},{"issue":"6","key":"21934_CR17","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis, D. N. et al. The 2016 World Health Organization classification of tumors of the central nervous system: A summary. Acta Neuropathol. 131(6), 803\u2013820. https:\/\/doi.org\/10.1007\/s00401-016-1545-1 (2016).","journal-title":"Acta Neuropathol."},{"issue":"12 Suppl 2","key":"21934_CR18","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1093\/neuonc\/noad258.PMID:38437669;PMCID:PMC10911794","volume":"26","author":"CL Tseng","year":"2024","unstructured":"Tseng, C. L. et al. Evolving concepts in margin strategies and adaptive radiotherapy for glioblastoma: A new future is on the horizon. Neuro Oncol. 26(12 Suppl 2), S3\u2013S16. https:\/\/doi.org\/10.1093\/neuonc\/noad258.PMID:38437669;PMCID:PMC10911794 (2024).","journal-title":"Neuro Oncol."},{"issue":"3","key":"21934_CR19","doi-asserted-by":"publisher","first-page":"e239","DOI":"10.1016\/j.prro.2023.01.008","volume":"13","author":"MG Mendoza","year":"2023","unstructured":"Mendoza, M. G. et al. Patterns of progression in patients with newly diagnosed glioblastoma treated with 5-mm margins in a phase 1\/2 trial of 5-fraction stereotactic radiosurgery with concurrent and adjuvant temozolomide. Pract. Radiat. Oncol. 13(3), e239\u2013e245. https:\/\/doi.org\/10.1016\/j.prro.2023.01.008 (2023).","journal-title":"Pract. Radiat. Oncol."},{"key":"21934_CR20","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13014-020-01584-6","volume":"15","author":"JC Trone","year":"2020","unstructured":"Trone, J. C. et al. Survival after hypofractionation in glioblastoma: A systematic review and meta-analysis. Radiat. Oncol. 15, 145. https:\/\/doi.org\/10.1186\/s13014-020-01584-6 (2020).","journal-title":"Radiat. Oncol."},{"issue":"2","key":"21934_CR21","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s11060-021-03926-0","volume":"156","author":"RJ Klement","year":"2022","unstructured":"Klement, R. J. et al. Accelerated hyper-versus normofractionated radiochemotherapy with temozolomide in patients with glioblastoma: A multicenter retrospective analysis. J. Neurooncol. 156(2), 407\u2013417. https:\/\/doi.org\/10.1007\/s11060-021-03926-0 (2022).","journal-title":"J. Neurooncol."},{"key":"21934_CR22","doi-asserted-by":"publisher","first-page":"9283","DOI":"10.1038\/s41598-024-60154-y","volume":"14","author":"S Takano","year":"2024","unstructured":"Takano, S. et al. Simultaneous boost radiotherapy versus conventional dose radiotherapy for patients with newly diagnosed glioblastoma: A multi-institutional analysis. Sci. Rep. 14, 9283. https:\/\/doi.org\/10.1038\/s41598-024-60154-y (2024).","journal-title":"Sci. Rep."},{"key":"21934_CR23","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12885-019-5317-x","volume":"19","author":"A Laprie","year":"2019","unstructured":"Laprie, A. et al. Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: The SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging. BMC Cancer 19, 167. https:\/\/doi.org\/10.1186\/s12885-019-5317-x (2019).","journal-title":"BMC Cancer"},{"issue":"1","key":"21934_CR24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13014-023-02203-w","volume":"18","author":"H Liu","year":"2023","unstructured":"Liu, H., Zhang, L., Tan, Y., Jiang, Y. & Lu, H. Observation of the delineation of the target volume of radiotherapy in adult-type diffuse gliomas after temozolomide-based chemoradiotherapy: Analysis of recurrence patterns and predictive factors. Radiat. Oncol. 18(1), 16. https:\/\/doi.org\/10.1186\/s13014-023-02203-w (2023).","journal-title":"Radiat. Oncol."},{"issue":"3","key":"21934_CR25","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/nop\/npae013","volume":"11","author":"SS Lo","year":"2024","unstructured":"Lo, S. S., Tseng, C. L. & Sahgal, A. Target delineation for glioblastoma-Is it time to sever historical ties?. Neurooncol Pract. 11(3), 221\u2013222. https:\/\/doi.org\/10.1093\/nop\/npae013 (2024).","journal-title":"Neurooncol Pract."},{"key":"21934_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2022.11.024","volume":"181","author":"G Minniti","year":"2023","unstructured":"Minniti, G. et al. Feasibility of clinical target volume reduction for glioblastoma treated with standard chemoradiation based on patterns of failure analysis. Radiother Oncol. 181, 109435. https:\/\/doi.org\/10.1016\/j.radonc.2022.11.024 (2023) (Epub 2022 Dec 16 PMID: 36529439).","journal-title":"Radiother Oncol."},{"issue":"2020","key":"21934_CR27","doi-asserted-by":"publisher","first-page":"4258989","DOI":"10.1155\/2020\/4258989","volume":"18","author":"P Liu","year":"2020","unstructured":"Liu, P. et al. Comparison of dosimetric gains provided by intensity-modulated radiotherapy, volume-modulated arc therapy, and helical tomotherapy for high-grade glioma. Biomed. Res. Int. 18(2020), 4258989. https:\/\/doi.org\/10.1155\/2020\/4258989 (2020).","journal-title":"Biomed. Res. Int."},{"issue":"4","key":"21934_CR28","doi-asserted-by":"publisher","first-page":"e13062","DOI":"10.1111\/bpa.13062","volume":"32","author":"BT Whitfield","year":"2022","unstructured":"Whitfield, B. T. & Huse, J. T. Classification of adult-type diffuse gliomas: Impact of the World Health Organization 2021 update. Brain Pathol. 32(4), e13062. https:\/\/doi.org\/10.1111\/bpa.13062 (2022).","journal-title":"Brain Pathol."},{"key":"21934_CR29","doi-asserted-by":"publisher","DOI":"10.1200\/PO.21.00112","author":"JL Fleming","year":"2021","unstructured":"Fleming, J. L. et al. Long-term report of a comprehensive molecular and genomic analysis in NRG oncology\/RTOG 0424: A phase II study of radiation and temozolomide in high-risk grade II glioma. JCO Precis. Oncol. https:\/\/doi.org\/10.1200\/PO.21.00112 (2021).","journal-title":"JCO Precis. Oncol."},{"issue":"29","key":"21934_CR30","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.1200\/JCO.19.02983","volume":"38","author":"EH Bell","year":"2020","unstructured":"Bell, E. H. et al. Comprehensive genomic analysis in NRG oncology\/RTOG 9802: A phase III trial of radiation versus radiation plus procarbazine, lomustine (CCNU), and vincristine in high-risk low-grade glioma. J. Clin. Oncol. 38(29), 3407\u20133417. https:\/\/doi.org\/10.1200\/JCO.19.02983 (2020).","journal-title":"J. Clin. Oncol."},{"key":"21934_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2025.03.043","author":"JL Fleming","year":"2025","unstructured":"Fleming, J. L. et al. Comprehensive molecular analysis in NRG oncology\/RTOG 9813: A phase III study of radiation and temozolomide versus radiation and BCNU\/CCNU in anaplastic astrocytoma. Int. J. Radiat. Oncol. Biol. Phys. https:\/\/doi.org\/10.1016\/j.ijrobp.2025.03.043 (2025).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"2","key":"21934_CR32","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ijrobp.2022.05.036","volume":"114","author":"S Tewari","year":"2022","unstructured":"Tewari, S. et al. Sex-specific differences in low-grade glioma presentation and outcome. Int. J. Radiat. Oncol. Biol. Phys. 114(2), 283\u2013292. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.05.036 (2022).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"11","key":"21934_CR33","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1093\/neuonc\/noac190","volume":"24","author":"DD Shi","year":"2022","unstructured":"Shi, D. D. et al. Improved survival among females and association with lymphopenia in patients with newly diagnosed glioblastoma. Neuro Oncol. 24(11), 2005\u20132007. https:\/\/doi.org\/10.1093\/neuonc\/noac190 (2022).","journal-title":"Neuro Oncol."},{"issue":"3","key":"21934_CR34","doi-asserted-by":"publisher","first-page":"486","DOI":"10.3390\/jcm11030486.PMID:35159938;PMCID:PMC8837060","volume":"11","author":"B Tavelin","year":"2022","unstructured":"Tavelin, B. & Malmstr\u00f6m, A. Sex differences in glioblastoma- findings from the Swedish National Quality Registry for Primary Brain Tumors between 1999\u20132018. J Clin Med. 11(3), 486. https:\/\/doi.org\/10.3390\/jcm11030486.PMID:35159938;PMCID:PMC8837060 (2022).","journal-title":"J Clin Med."},{"issue":"41","key":"21934_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2023.100626","volume":"5","author":"L Allwohn","year":"2023","unstructured":"Allwohn, L. et al. Treating oligodendroglioma - An analysis of a homogeneous 1p\/19q-codeleted and isocitrate dehydrogenase-mutant patient cohort. Clin. Transl. Radiat. Oncol. 5(41), 100626. https:\/\/doi.org\/10.1016\/j.ctro.2023.100626 (2023).","journal-title":"Clin. Transl. Radiat. Oncol."},{"issue":"13","key":"21934_CR36","doi-asserted-by":"publisher","first-page":"1200815","DOI":"10.3389\/fonc.2023.1200815","volume":"6","author":"X Guo","year":"2023","unstructured":"Guo, X. et al. Histological and molecular glioblastoma, IDH-wildtype: A real-world landscape using the 2021 WHO classification of central nervous system tumors. Front. Oncol. 6(13), 1200815. https:\/\/doi.org\/10.3389\/fonc.2023.1200815 (2023).","journal-title":"Front. Oncol."},{"issue":"10","key":"21934_CR37","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1093\/neuonc\/noae108","volume":"26","author":"Hegi ME, Oppong F, Perry J, Wick W, Henriksson R, Laperriere NJ, Gorlia T, Malmstr\u00f6m A, Weller M, for the NCBTSG, NOA, CCTG, and EORTC-BTG","year":"2024","unstructured":"Hegi ME, Oppong F, Perry J, Wick W, Henriksson R, Laperriere NJ, Gorlia T, Malmstr\u00f6m A, Weller M, for the NCBTSG, NOA, CCTG, and EORTC-BTG. No benefit from TMZ treatment in glioblastoma with truly unmethylated MGMT promoter: Reanalysis of the CE.6 and the pooled Nordic\/NOA-08 trials in elderly glioblastoma patients. Neuro-Oncology 26(10), 1867\u20131875. https:\/\/doi.org\/10.1093\/neuonc\/noae108 (2024).","journal-title":"Neuro-Oncology"},{"issue":"1","key":"21934_CR38","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1007\/s00701-024-06300-x","volume":"166","author":"P Ghimire","year":"2024","unstructured":"Ghimire, P. et al. MGMT methylation and its prognostic significance in inoperable IDH-wildtype glioblastoma: The MGMT-GBM study. Acta Neurochir (Wien). 166(1), 394. https:\/\/doi.org\/10.1007\/s00701-024-06300-x (2024).","journal-title":"Acta Neurochir (Wien)."},{"key":"21934_CR39","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s11060-025-04952-y","volume":"172","author":"J Pham","year":"2025","unstructured":"Pham, J. et al. Treatment practices and survival outcomes for IDH-wildtype glioblastoma patients according to MGMT promoter methylation status: Insights from the U. S. National Cancer Database. J. Neurooncol. 172, 655\u2013665. https:\/\/doi.org\/10.1007\/s11060-025-04952-y (2025).","journal-title":"J. Neurooncol."},{"issue":"12","key":"21934_CR40","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1158\/1078-0432.CCR-21-4283","volume":"28","author":"CMS Tesileanu","year":"2022","unstructured":"Tesileanu, C. M. S. et al. Temozolomide and radiotherapy versus radiotherapy alone in patients with glioblastoma, IDH-wildtype: Post hoc analysis of the EORTC randomized phase III CATNON trial. Clin. Cancer Res. 28(12), 2527\u20132535. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-4283 (2022).","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"21934_CR41","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S1470-2045(21)00090-5","volume":"22","author":"MJ van den Bent","year":"2021","unstructured":"van den Bent, M. J. et al. Adjuvant and concurrent temozolomide for 1p\/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053\u201322054): Second interim analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 22(6), 813\u2013823. https:\/\/doi.org\/10.1016\/S1470-2045(21)00090-5 (2021).","journal-title":"Lancet Oncol."},{"issue":"15","key":"21934_CR42","doi-asserted-by":"publisher","first-page":"1426635","DOI":"10.3389\/fimmu.2024.1426635","volume":"1","author":"\u0141 Kuncman","year":"2024","unstructured":"Kuncman, \u0141 et al. Early lymphocyte levels and low doses radiation exposure of lung predict lymphopenia in radiotherapy for lung cancer. Front. Immunol. 1(15), 1426635. https:\/\/doi.org\/10.3389\/fimmu.2024.1426635 (2024).","journal-title":"Front. Immunol."},{"issue":"1","key":"21934_CR43","doi-asserted-by":"publisher","first-page":"14372","DOI":"10.1038\/s41598-023-41301-3","volume":"13","author":"CI Yoon","year":"2023","unstructured":"Yoon, C. I. et al. Prognostic impact of radiotherapy-induced-lymphopenia in patients treated with breast-conservative surgery. Sci. Rep. 13(1), 14372. https:\/\/doi.org\/10.1038\/s41598-023-41301-3 (2023).","journal-title":"Sci. Rep."},{"key":"21934_CR44","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.radonc.2022.01.003","volume":"168","author":"D Dai","year":"2022","unstructured":"Dai, D., Tian, Q., Shui, Y., Li, J. & Wei, Q. The impact of radiation induced lymphopenia in the prognosis of head and neck cancer: A systematic review and meta-analysis. Radiother. Oncol. 168, 28\u201336. https:\/\/doi.org\/10.1016\/j.radonc.2022.01.003 (2022).","journal-title":"Radiother. Oncol."},{"issue":"49","key":"21934_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2024.100852","volume":"6","author":"E Prades-Sagarra","year":"2024","unstructured":"Prades-Sagarra, E., Yaromina, A. & Dubois, L. J. Understanding the impact of radiation-induced lymphopenia: Preclinical and clinical research perspectives. Clin. Transl. Radiat. Oncol. 6(49), 100852. https:\/\/doi.org\/10.1016\/j.ctro.2024.100852 (2024).","journal-title":"Clin. Transl. Radiat. Oncol."},{"issue":"4","key":"21934_CR46","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1055\/s-0042-1753504","volume":"11","author":"S Mallick","year":"2022","unstructured":"Mallick, S. et al. A systematic review and meta-analysis of the impact of radiation-related lymphopenia on outcomes in high-grade gliomas. South Asian J. Cancer 11(4), 361\u2013369. https:\/\/doi.org\/10.1055\/s-0042-1753504 (2022).","journal-title":"South Asian J. Cancer"},{"issue":"05","key":"21934_CR47","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.ijrobp.2015.04.005","volume":"92","author":"J Huang","year":"2015","unstructured":"Huang, J. et al. Clinical and dosimetric predictors of acute severe lymphopenia during radiation therapy and concurrent temozolomide for high-grade glioma. Int. J. Radiat. Oncol. Biol. Phys. 92(05), 1000\u20131007 (2015).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"01","key":"21934_CR48","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ijrobp.2018.01.069","volume":"101","author":"S Rudra","year":"2018","unstructured":"Rudra, S. et al. Effect of radiation treatment volume reduction on lymphopenia in patients receiving chemoradiotherapy for glioblastoma. Int. J. Radiat. Oncol. Biol. Phys. 101(01), 217\u2013225 (2018).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"01","key":"21934_CR49","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13014-019-1256-6","volume":"14","author":"HK Byun","year":"2019","unstructured":"Byun, H. K. et al. Clinical predictors of radiationinduced lymphopenia in patients receiving chemoradiation for glioblastoma: Clinical usefulness of intensity-modulated radiotherapy in the immuno-oncology era. Radiat. Oncol. 14(01), 51 (2019).","journal-title":"Radiat. Oncol."},{"issue":"06","key":"21934_CR50","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1002\/cam4.2159","volume":"8","author":"LL Ye","year":"2019","unstructured":"Ye, L. L. et al. Dosimetry of the brain and hypothalamus predicting acute lymphopenia and the survival of glioma patients with postoperative radiotherapy. Cancer Med. 8(06), 2759\u20132768 (2019).","journal-title":"Cancer Med."},{"issue":"02","key":"21934_CR51","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1093\/neuonc\/noaa182","volume":"23","author":"R Mohan","year":"2021","unstructured":"Mohan, R. et al. Proton therapy reduces the likelihood of high-grade radiation-induced lymphopenia in glioblastoma patients: Phase II randomized study of protons vs photons. Neuro-oncology 23(02), 284\u2013294 (2021).","journal-title":"Neuro-oncology"},{"issue":"10","key":"21934_CR52","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.3389\/fonc.2020.01662","volume":"2","author":"A Palpan Flores","year":"2020","unstructured":"Palpan Flores, A. et al. Assessment of pre-operative measurements of tumor size by MRI methods as survival predictors in wild type IDH glioblastoma. Front Oncol. 2(10), 1662. https:\/\/doi.org\/10.3389\/fonc.2020.01662 (2020).","journal-title":"Front Oncol."},{"issue":"4","key":"21934_CR53","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.ijrobp.2018.11.004","volume":"103","author":"JM Cherlow","year":"2019","unstructured":"Cherlow, J. M. et al. Conformal radiation therapy for pediatric patients with low-grade glioma: Results from the children\u2019s oncology group phase 2 study ACNS0221. Int. J. Radiat. Oncol. Biol. Phys. 103(4), 861\u2013868. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.11.004 (2019).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"5","key":"21934_CR54","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1093\/nop\/npz017","volume":"6","author":"CH Chapman","year":"2019","unstructured":"Chapman, C. H. et al. Reirradiation of recurrent high-grade glioma and development of prognostic scores for progression and survival. Neurooncol. Pract. 6(5), 364\u2013374. https:\/\/doi.org\/10.1093\/nop\/npz017 (2019).","journal-title":"Neurooncol. Pract."},{"issue":"1","key":"21934_CR55","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.prro.2018.06.001","volume":"9","author":"K Guram","year":"2019","unstructured":"Guram, K. et al. Using smaller-than-standard radiation treatment margins does not change survival outcomes in patients with high-grade gliomas. Pract. Radiat. Oncol. 9(1), 16\u201323. https:\/\/doi.org\/10.1016\/j.prro.2018.06.001 (2019).","journal-title":"Pract. Radiat. Oncol."},{"key":"21934_CR56","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13014-023-02203-w","volume":"18","author":"H Liu","year":"2023","unstructured":"Liu, H. et al. Observation of the delineation of the target volume of radiotherapy in adult-type diffuse gliomas after temozolomide-based chemoradiotherapy: Analysis of recurrence patterns and predictive factors. Radiat. Oncol. 18, 16. https:\/\/doi.org\/10.1186\/s13014-023-02203-w (2023).","journal-title":"Radiat. Oncol."},{"issue":"3","key":"21934_CR57","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1093\/nop\/npae009","volume":"11","author":"MT Yilmaz","year":"2024","unstructured":"Yilmaz, M. T. et al. Comparison of different target volume delineation strategies based on recurrence patterns in adjuvant radiotherapy for glioblastoma. Neurooncol. Pract. 11(3), 275\u2013283. https:\/\/doi.org\/10.1093\/nop\/npae009 (2024).","journal-title":"Neurooncol. Pract."},{"issue":"12","key":"21934_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.726561","volume":"4","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y. et al. Prognostic value and risk factors of treatment-related lymphopenia in malignant glioma patients treated with chemoradiotherapy: A systematic review and meta-analysis. Front. Neurol. 4(12), 726561. https:\/\/doi.org\/10.3389\/fneur.2021.726561 (2022).","journal-title":"Front. Neurol."},{"key":"21934_CR59","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13014-023-02393-3","volume":"19","author":"AM Saeed","year":"2024","unstructured":"Saeed, A. M. et al. Systematic review and pooled analysis of the impact of treatment-induced lymphopenia on survival of glioblastoma patients. Radiat. Oncol. 19, 36. https:\/\/doi.org\/10.1186\/s13014-023-02393-3 (2024).","journal-title":"Radiat. Oncol."},{"issue":"47","key":"21934_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2024.100799","volume":"22","author":"N Kim","year":"2024","unstructured":"Kim, N. et al. Nomogram for radiation-induced lymphopenia in patients receiving intensity-modulated radiotherapy based-chemoradiation therapy for newly diagnosed glioblastoma: A multi-institutional study. Clin. Transl. Radiat. Oncol. 22(47), 100799. https:\/\/doi.org\/10.1016\/j.ctro.2024.100799 (2024).","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"21934_CR61","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13046-023-02621-4","volume":"42","author":"TN Pham","year":"2023","unstructured":"Pham, T. N. et al. Beyond lymphopenia, unraveling radiation-induced leucocyte subpopulation kinetics and mechanisms through modeling approaches. J. Exp. Clin. Cancer Res. 42, 50. https:\/\/doi.org\/10.1186\/s13046-023-02621-4 (2023).","journal-title":"J. Exp. Clin. Cancer Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-21934-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-21934-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-21934-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:26:26Z","timestamp":1761830786000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-21934-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["21934"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-21934-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7003502\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"assertion":[{"value":"29 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38011"}}